[1]
B. Celesia, “IS IT SAFE AND COST SAVING TO DEFER THE CD4+ CELL COUNT MONITORING IN STABLE PATIENTS ON ART WITH MORE THAN 350 OR 500 CELLS/µL?”, MJHID, vol. 11, no. 1, p. e2019063, Oct. 2019.